This browser is older than PubPhys supports. Every page can be read, but signing in to contribute, voting and signing need Safari 15.4, Chrome or Edge 99, Firefox 97 or newer. Browsers
All problems
65 problems
Starting order drafted by AI. Votes change it. How ranking works
-
Construct a model converting a spatially modulated dose distribution with peak-to-valley ratios of 10 to 100 into an equivalent uniform dose for tumour control and for normal-tissue complication, valid for single fractions of $10^{3}$ to $10^{4}$ rad peak. The linear-quadratic formalism with $\alpha$ and $\beta$ applied voxel by voxel is the current default and is known to fail. An answer is a model validated against measured outcomes across several geometries.
-
Accelerator neutron sources meeting epithermal beam requirements
Partially resolved 49Design an accelerator-driven source giving epithermal neutron flux above $10^9\,\mathrm{per}\,\mathrm{cm}^2\,\mathrm{per}\,\mathrm{s}$ at the beam port with fast-neutron and photon dose per epithermal neutron below the IAEA-recommended limits (of order $2 \times 10^{-11}$ $\mathrm{rad}\ \mathrm{cm}^{2}$ each), using $\mathrm{Li}-7(p,n)$, $\mathrm{Be}-9(p,n)$ or $(d,n)$ reactions, with target lifetime of at least hundreds of treatment hours under proton-induced blistering and heat loads of order $10^{11}\,\mathrm{erg}/\mathrm{s}$. An answer is a source with measured spectrum, flux and target lifetime meeting all criteria.
-
Achieve transcranial focal placement accurate to 1 mm and pressure prediction accurate to 10 percent at 0.2 to 1 MHz without computed tomography of the skull, by inferring the skull acoustic properties (sound speed $2.4\,\mathrm{x}\,10^{5} \text{ to } 3.0\,\mathrm{x}\,10^{5}\,\mathrm{cm}/\mathrm{s}$, density, absorption, shear conversion) from ultrasound or magnetic resonance data. An answer is a method with verified focal position and amplitude in human skulls.
-
Achieve activity quantification to better than 10 percent for therapeutic nuclides with sparse or complex photon emission, notably Ac-225 at administered activities of order 2.7 microCi per kg (about 0.2 mCi per patient), imaged through the daughter gamma lines at 218 keV (Fr-221) and 440 keV (Bi-213), and Pb-212 at 239 keV, including scatter, collimator septal penetration and partial-volume correction. An answer is a calibrated imaging and reconstruction protocol with measured accuracy.
-
For gold nanoparticles of 2 to 50 nm diameter at intracellular mass fractions of 0.1 to 1 percent, irradiated by 6 MV photon beams, the macroscopic dose enhancement computed by Monte Carlo transport is of order 1 percent or less, while reported sensitizer enhancement ratios at 10 percent survival range from about 1.1 to 1.5. Identify the mechanism, or combination, that accounts for the excess: nanometre-scale dose heterogeneity from photoelectron and Auger emission near the particle, surface-catalysed radical production, or biological pathways such as mitochondrial or cell-cycle effects. An answer is a model that predicts the enhancement ratio as a function of particle size, coating, location and beam energy without refitting.
-
Measure tissue temperature during focused ultrasound heating to an accuracy of 1 K with a spatial resolution of 2 mm and an update rate above 1 Hz, in fat-containing and moving tissue, using acoustic observables such as speed-of-sound shift, thermal strain, or backscatter change. An answer is a demonstrated technique meeting these figures against an independent temperature reference.
-
Measure and model partial charge-changing and isotopic production cross sections for projectiles of Z from 2 to 10 at 100 to 450 MeV per nucleon on hydrogen, carbon, nitrogen, oxygen and calcium targets, to about 5 percent, including fragment angular and energy distributions. An answer is a cross-section set that lets Monte Carlo transport reproduce measured depth-dose tails to within 1 percent of peak dose.
-
Forward model for charge sharing and pulse pileup
Partially resolved 47Construct a detector response model giving the recorded energy spectrum from the incident one, including charge sharing between pixels of 200 to 500 micron pitch, K-escape of the sensor material, and pulse pileup at count rates of $10^{8}$ to $10^{9}$ counts per second per $\mathrm{mm}^2$, accurate enough that material decomposition bias stays below 1 percent. An answer is a validated response matrix with its calibration procedure.
-
Quantify the dose reduction factor achievable with photon-counting relative to energy-integrating detection at matched task-based detectability, separately for high-contrast spatial resolution tasks, low-contrast detection tasks and material quantification tasks, for patient thicknesses of 20 to 45 cm. An answer is a factor with uncertainty per task class.
-
Sensor material choice for clinical count rates
Contested 46Compare cadmium telluride, cadmium zinc telluride and deep-silicon sensors on detection efficiency at 20 to 140 keV, charge-transport polarization at fluxes above $10^{8}$ counts per second per $\mathrm{mm}^{2}$, charge-sharing fraction at a given pixel pitch, and K-escape, under identical clinical conditions. An answer is a classification of which material wins for which imaging task, with the physical reasons.
-
Determine whether bystander signalling, genomic instability and abscopal responses change organ-level risk at doses below 10 rad in vivo, relative to the prediction from directly hit cells alone. Required: dose range, signalling distance in tissue, and persistence. An answer is a quantified modification factor or a demonstration that it is negligible.
-
Develop a three-dimensional dosimeter with spatial resolution of 1 mm, dose accuracy of 2 percent, energy and dose-rate response within 1 percent of water, and traceability to a primary standard. Candidates: radiochromic and polymer gels, plastic scintillator volumes with optical tomography, and Cherenkov imaging. An answer is a demonstrated system meeting all four criteria simultaneously.
-
Measure the B-10 concentration distribution at 1 to 10 micron resolution in tumour, tumour margin and normal tissue for the clinical carriers (boronophenylalanine and sodium borocaptate), including the fraction of tumour cells with low uptake, and convert it into a microdosimetric specific-energy distribution for the $\alpha$ and Li-7 fragments of ranges about 9 and 5 micron. An answer is a measured distribution and the resulting ratio of cellular to bulk-averaged dose.
-
Determine the relative contribution of microvascular preservation and of immune activation to the differential response of spatially fractionated fields, by measuring the effect in immunodeficient versus immunocompetent models and with and without vascular protection, at fixed peak and valley dose. An answer assigns the dominant channel per tissue and tumour type.
-
Determine the tolerance surface in the plane of valley dose and peak-to-valley dose ratio, for beam widths of 25 to 1000 micron and spacing of 200 to 4000 micron, in central nervous system, skin and lung. State which of peak dose, valley dose or their ratio controls toxicity for each tissue. An answer is a tolerance criterion with measured thresholds in rad.
-
Determine the mean excitation energy $I$ of liquid water, which enters the Bethe stopping-power formula, to an uncertainty below 1 eV; the ICRU 90 recommendation is $I = 78 \pm 2\,\mathrm{eV}$, and published experimental and dielectric-response values spread over several eV around it. An answer is a value with uncertainty consistent between direct range or stopping-power measurements and optical-data calculations.
-
Effective range extension at the distal falloff
Partially resolved 44Quantify the shift in the biologically effective range at the distal edge of a spread-out Bragg peak, where $\mathrm{LET}_d$ exceeds about $5\,\mathrm{keV}/\mathrm{micron}$, for normal tissues of $\alpha/\beta$ near $200\,\mathrm{rad}$. Express it as a range extension in mm of water-equivalent thickness as a function of beam energy and modulation width. An answer is a number with uncertainty, per endpoint.
-
Compute absorbed dose at the scale of 10 to 1000 micron in kidney (glomerulus, proximal tubule, interstitium) and in red marrow cavities, including non-uniform uptake and beta particle ranges in tissue of about 0.7 mm mean (2 mm maximum) for Lu-177 and about 2.5 mm mean (11 mm maximum) for Y-90, and relate it to the organ-average dose currently used. An answer is a set of small-scale to organ-average dose ratios with their uncertainty.
-
Determine the minimum detectable concentration of K-edge elements (iodine at 33.2 keV, gadolinium at 50.2 keV, and higher-$Z$ labels such as tantalum, gold and bismuth) in a 30 cm diameter water phantom at clinical dose, as a function of detector energy resolution, bin count and photon flux. An answer is a detection-limit formula in mg per cm^3 with its dependence on these quantities.
-
Determine the yields of hydroperoxyl, peroxyl and organic radicals, and of hydrogen peroxide, as a function of instantaneous dose rate from $100\ \text{to}\ 10^{9}\,\mathrm{rad}/\mathrm{s}$ in oxygenated aqueous and lipid-containing media, including inter-track overlap. Required inputs: second-order rate constants, radical diffusion lengths and the spatial density of tracks at a given dose per pulse. An answer is measured and computed yield curves $G(\text{dose rate})$ accurate to about 10 percent.
-
Derive a scaling relation for the therapeutic ratio as a function of beam width w, centre-to-centre spacing s, and depth, including beam broadening by multiple scattering for protons and by scattered photons for x-rays, so that the pattern merges into a uniform field at the target while staying fractionated in normal tissue. An answer is a design rule for w and s with the physical quantities that set them.
-
Determine the mean intra-to-extracellular water exchange time $\tau_{ex}$ in human and rodent grey matter, which reported analyses place anywhere from about 10 ms to over 100 ms, using diffusion-time-dependent kurtosis, filter-exchange imaging or multi-dimensional relaxation-diffusion methods, while separating exchange from structural time dependence. An answer is a value with uncertainty that is consistent across methods.
-
Quantify cell killing per decay for Auger-electron emitters (I-125, In-111, Tc-99m, Ga-67) localized in the nucleus, the cytoplasm, the mitochondria and the cell membrane, and compare with the absorbed dose to the nucleus computed by cellular S-values (tabulated dose per decay between cell compartments) and track-structure codes. An answer is a ratio of observed to predicted effect per compartment, and the identification of any non-nuclear target or signalling pathway needed to explain a ratio above 1.
-
Smallest axon diameter measurable by diffusion MRI in humans
Partially resolved 40Determine the resolution limit on axon radius $r$ from the diffusion signal perpendicular to axons as a function of maximal gradient amplitude $G$ (30 to 50 G/cm in dedicated human scanners), diffusion time and signal-to-noise ratio, given that the signal attenuation scales as $r^4 G^2$ in the wide-pulse limit, and whether the estimated effective radius, weighted toward the largest axons, can be related to histological radius distributions. An answer is the limit in micron and a demonstrated agreement or disagreement with histology.
-
Detector correction factors in millimetre-scale fields
Partially resolved 40Determine field-output correction factors for active and passive detectors in photon fields of equivalent square side 2 to 20 mm, where lateral charged-particle equilibrium fails and source occlusion sets in, to a standard uncertainty below 1 percent. Required: detector-specific perturbation factors from Monte Carlo with validated geometry and from independent measurement. An answer is a correction-factor set with that uncertainty.
-
Compute the transient oxygen tension during a 100 ms, 2000 rad exposure using measured radiolytic oxygen consumption of about 0.2 to 0.5 micromolar per 100 rad, tissue diffusion constants and capillary resupply, and test whether the resulting dip at physiological $pO2$ of about 5 to 40 mmHg produces the measured change in oxygen enhancement ratio. An answer is yes or no with an error budget on consumption yield, diffusion and perfusion.
-
Determine whether high-Z nanoparticles at clinically achievable concentrations (below about 1 mg per g of tissue) increase cell killing in proton beams of 10 to 200 MeV and carbon-ion beams of 50 to 400 MeV per nucleon beyond the computed dose increase, which is of order 0.1 percent. An answer is yes or no with a measured enhancement ratio and its uncertainty under controlled particle uptake, plus the physical or chemical channel responsible if yes.
-
Establish the coincidence time resolution, detector solid-angle coverage and count statistics at which direct event-by-event image formation matches or beats iterative tomographic reconstruction in task-based detectability for lesions of 5 to 10 mm. An answer is the threshold condition, stated in ps and counts, with the comparison metric.
-
Chamber response in treatment-strength magnetic fields
Partially resolved 38Determine the magnetic-field correction factor for ionization chambers and solid-state detectors in fields of 3.5 to 15 kG, as a function of chamber axis orientation relative to the magnetic field and beam, cavity dimensions and gas, to below 0.5 percent. Include the electron return effect at tissue and air interfaces. An answer is a validated correction factor set and a primary standard valid in field.
-
Design a detector measuring depth of interaction to better than 2 mm in crystals 20 mm deep while keeping coincidence time resolution below 100 ps, with the light-transport delay correlation between the two measurements corrected rather than averaged. An answer is a demonstrated detector with both figures met simultaneously.